DK0909175T3 - Ikke-vandige, protiske peptidformuleringer - Google Patents

Ikke-vandige, protiske peptidformuleringer

Info

Publication number
DK0909175T3
DK0909175T3 DK97930181T DK97930181T DK0909175T3 DK 0909175 T3 DK0909175 T3 DK 0909175T3 DK 97930181 T DK97930181 T DK 97930181T DK 97930181 T DK97930181 T DK 97930181T DK 0909175 T3 DK0909175 T3 DK 0909175T3
Authority
DK
Denmark
Prior art keywords
peptide formulations
aqueous protic
protic peptide
aqueous
formulations
Prior art date
Application number
DK97930181T
Other languages
Danish (da)
English (en)
Inventor
James B Eckenhoff
Cynthia L Stevenson
Sally A Tao
Steven J Prestrelski
Jeremy C Wright
Joe Leonard
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DK0909175T3 publication Critical patent/DK0909175T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK97930181T 1996-07-03 1997-07-01 Ikke-vandige, protiske peptidformuleringer DK0909175T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2112996P 1996-07-03 1996-07-03
PCT/US1997/010815 WO1998000152A1 (en) 1996-07-03 1997-07-01 Non-aqueous protic peptide formulations

Publications (1)

Publication Number Publication Date
DK0909175T3 true DK0909175T3 (da) 2003-09-29

Family

ID=21802501

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97930181T DK0909175T3 (da) 1996-07-03 1997-07-01 Ikke-vandige, protiske peptidformuleringer

Country Status (27)

Country Link
EP (1) EP0909175B1 (xx)
JP (3) JP2001504802A (xx)
CN (1) CN1231256C (xx)
AR (1) AR008060A1 (xx)
AT (1) ATE241997T1 (xx)
AU (1) AU737664B2 (xx)
BR (1) BR9710130A (xx)
CA (1) CA2259403A1 (xx)
CO (1) CO4890854A1 (xx)
CZ (1) CZ433898A3 (xx)
DE (1) DE69722620T2 (xx)
DK (1) DK0909175T3 (xx)
ES (1) ES2201306T3 (xx)
HU (1) HUP9903942A3 (xx)
ID (1) ID19165A (xx)
IL (1) IL127769A (xx)
MY (1) MY121684A (xx)
NO (1) NO323933B1 (xx)
NZ (1) NZ333580A (xx)
PL (1) PL189402B1 (xx)
PT (1) PT909175E (xx)
RO (1) RO119862B1 (xx)
RU (1) RU2203085C2 (xx)
SK (1) SK284490B6 (xx)
TW (1) TW491703B (xx)
WO (1) WO1998000152A1 (xx)
ZA (1) ZA975942B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2259403A1 (en) * 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004031011D1 (de) * 2003-04-25 2011-02-24 Boston Scient Scimed Inc Feste arzneimittelformulierung und vorrichtung zu ihrer aufbewahrung und kontrollierten abgabe
CN102784386A (zh) * 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CN101678112B (zh) * 2007-01-19 2016-08-31 哈南亚有限公司 用于递送治疗剂的方法和组合物
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010009291A1 (en) 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
BRPI0917807A2 (pt) 2008-08-15 2019-11-19 Forest Laboratories Holdings Ltd formulação sólida estável de um polipeptídeo agonista de recepto gc-c adequada para administração oral
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CN104323981B (zh) 2009-09-28 2019-03-12 精达制药公司 基本稳态药物递送的快速建立和/或终止
PL2536742T3 (pl) 2010-02-17 2017-11-30 Ironwood Pharmaceuticals, Inc. Leczenie zaburzeń żołądkowo-jelitowych
JP5921545B2 (ja) 2010-08-11 2016-05-24 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの安定な製剤
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN104053449B (zh) 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
WO2014124096A1 (en) * 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
EP3372224A1 (en) 2017-03-07 2018-09-12 Alrise Biosystems GmbH New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
JP2851627B2 (ja) * 1987-10-15 1999-01-27 シンテックス（ユー・エス・エイ）インコーポレイテッド 粉末形態ポリプペチド類の経鼻投与
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
DK0661989T3 (da) * 1992-09-21 1998-03-02 Upjohn Co Proteinsammensætninger med vedvarende frigivelse
DE69426292T2 (de) * 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
CA2259403A1 (en) * 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations

Also Published As

Publication number Publication date
PL189402B1 (pl) 2005-08-31
DE69722620D1 (de) 2003-07-10
CO4890854A1 (es) 2000-02-28
EP0909175A1 (en) 1999-04-21
AR008060A1 (es) 1999-12-09
ZA975942B (en) 1998-04-16
CN1231256C (zh) 2005-12-14
AU737664B2 (en) 2001-08-30
PL330869A1 (en) 1999-06-07
BR9710130A (pt) 1999-08-10
NZ333580A (en) 2000-06-23
CZ433898A3 (cs) 1999-04-14
JP2001504802A (ja) 2001-04-10
IL127769A0 (en) 1999-10-28
CA2259403A1 (en) 1998-01-08
NO986209L (no) 1998-12-30
ES2201306T3 (es) 2004-03-16
IL127769A (en) 2006-10-31
NO323933B1 (no) 2007-07-23
ID19165A (id) 1998-06-28
RU2203085C2 (ru) 2003-04-27
NO986209D0 (no) 1998-12-30
RO119862B1 (ro) 2005-05-30
SK179998A3 (en) 1999-05-07
TW491703B (en) 2002-06-21
AU3407397A (en) 1998-01-21
JP2010043105A (ja) 2010-02-25
CN1224356A (zh) 1999-07-28
MY121684A (en) 2006-02-28
HUP9903942A2 (hu) 2000-04-28
EP0909175B1 (en) 2003-06-04
WO1998000152A1 (en) 1998-01-08
ATE241997T1 (de) 2003-06-15
PT909175E (pt) 2003-10-31
SK284490B6 (sk) 2005-05-05
HUP9903942A3 (en) 2000-07-28
DE69722620T2 (de) 2004-04-29
JP2008195739A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
DK0909175T3 (da) Ikke-vandige, protiske peptidformuleringer
DK0921808T3 (da) Ikke-vandige, polære aprotiske peptidformuleringer
NO982097L (no) Peptider
NO982098L (no) Peptider
FI102434B (fi) Kahden taajuuden antenni
DE59711355D1 (de) Aktive Empfangsantenne
DE59708688D1 (de) Trennschalter
NO985680L (no) Peptidderivater
NO983849D0 (no) Peptidderivater
NO962167D0 (no) Deflektoranordning
NO985930L (no) Katodekonstruksjon
NO965214L (no) Deflektor
EA200000208A1 (ru) Иммуномодулятор с антимикробной и антимикобактериальной активностью, способ его получения и лекарственный препарат для лечения микобактериозов, хронических неспецифических заболеваний легких, заболеваний, передающихся половым путем, и иммунодефицита на их основе
NO20012283D0 (no) Koblede peptider
DE69813938D1 (de) Schaltröhre
NL1008516A1 (nl) Korstenbreker.
IT1303383B1 (it) Struttura di sci.
FI963062A0 (fi) Dubbelblad foer stoetblad, skopa, schaktblad
SE9802536D0 (sv) Novel peptides
NL1010046A1 (nl) Sproeistation.
TR199600559U (tr) Korumali kontaktör.
IT1294319B1 (it) Struttura di sci, snowboard o simile
BR7602376U (pt) Disposição construtiva de antenas
ES1039107Y (es) Seccionador perfeccionado.
ES1033732Y (es) Aplique.